DSIP and Sleep: Why This “Delta Sleep” Peptide Has Researchers (and Patients) Talking
10/22/2026
If you’ve ever done everything “right” for your sleep and still woken up unrefreshed, you know how frustrating it is. That frustration is why so many of my patients ask me about DSIP. It’s one of the most intriguing peptides in sleep science, and it deserves a thoughtful, honest look.
The short version
- DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid neuropeptide, first isolated in the 1970s and named for its link to deep, slow-wave sleep.
- In small clinical studies of people with chronic insomnia, researchers recorded better sleep efficiency, faster sleep onset, and improved daytime alertness.
- Many people who have tried DSIP report feeling that it helped their sleep. The formal research is still early, and larger modern trials are needed.
- DSIP is not FDA-approved, so it is best thought of as a promising area of study to discuss with your physician, alongside proven foundations like CBT-I.
Better sleep is about quality, not just hours
Eight hours in bed doesn’t guarantee restorative sleep. Clinicians look at sleep latency (how quickly you fall asleep), sleep efficiency (how much of your time in bed is actually spent asleep), and sleep architecture, including slow-wave (delta) sleep, the deepest stage of non-REM sleep. This is when much of the body’s physical restoration happens, and it’s the stage that gave DSIP its name.
What is DSIP?
DSIP was discovered in 1974 by a Swiss research group, which isolated it from the blood of rabbits in a sleep-like state. When infused into recipient rabbits, it increased delta and spindle activity on EEG and reduced motor activity. Researchers have since observed delta-sleep effects across several species, which is part of why scientific interest has endured for five decades. It’s also still an open question where in the body DSIP is made, which keeps it a fascinating subject for sleep researchers.
What the human research has found
The clinical studies are small and older, but the early signals were encouraging:
| Study | Design | What was reported |
|---|---|---|
| Kaeser, 1984 | Open-label, 7 patients with severe insomnia, series of 10 injections | Sleep normalized in all but one patient, with follow-up of 3 to 7 months. Mood and daytime performance improved as well. No control group. |
| Schneider-Helmert, 1987 | Placebo-controlled, double-blind, 14 chronic insomniacs, 7 nights | Improved night sleep, with efficiency reaching the level of normal controls, plus increased daytime alertness and performance. |
| Bes et al., 1992 | Double-blind, 16 chronic insomniacs, IV DSIP vs. placebo | Higher sleep efficiency and shorter sleep latency on polysomnography. Subjective sleep quality did not change, and the authors judged short-term benefit unlikely to be major. |
The 1987 investigators concluded that “The treatment substantially improved night sleep,” and two controlled studies measured objective gains in how efficiently people slept. Not every result has been reproduced, and a later review called DSIP “a still unresolved riddle.” To me that reads less like a closed door and more like an open invitation for better research.
Why DSIP is so interesting for more effective sleep
- Sleep efficiency. Spending more of your night actually asleep is one of the most meaningful markers of sleep quality.
- Falling asleep faster. Shorter latency to sleep was recorded on polysomnography in a double-blind trial.
- Daytime energy. Improved alertness and performance were reported in the 1987 study, which matters because daytime function is what insomnia takes from people.
- A different approach. DSIP is thought to work through sleep regulation and stress signaling rather than as a classic sedative, though its exact mechanism is still being studied.
What DSIP may offer
- Increased delta EEG activity in animal studies
- Better sleep efficiency and faster sleep onset in small human studies
- Improved daytime alertness in a double-blind study
- Consistent interest from researchers for five decades
- Positive experiences reported by many people who have tried it
What to keep in perspective
- It is not FDA-approved for insomnia or any other condition
- Modern, large, independent trials have not yet been done
- Its mechanism, ideal dosing, and long-term safety are not established
- It is not a substitute for CBT-I, and it does not treat sleep apnea or other medical causes of poor sleep
Other sleep options worth knowing about
Whatever you think about peptides, it helps to know the full toolbox. These are worth reviewing with a clinician, especially if you take other medications.
| Category | Examples | What to know |
|---|---|---|
| Behavioral therapy | CBT-I | First-line treatment for chronic insomnia, with lasting benefit and no medication risks. |
| Prescription | Zolpidem, eszopiclone; suvorexant, lemborexant, daridorexant; low-dose doxepin; trazodone (off-label) | Effective for many people. The “Z-drugs” carry an FDA boxed warning for complex sleep behaviors. Best used short-term and under supervision. |
| Over the counter | Diphenhydramine, doxylamine | Sedating antihistamines. Tolerance builds quickly and next-day grogginess is common. Best avoided in older adults. |
| Supplements | Melatonin, magnesium, glycine, L-theanine, valerian | Melatonin has modest benefit for sleep timing and onset. Evidence for the others is limited. Quality varies by brand. |
Start with the whole picture
Poor sleep is often a symptom of something else. Sleep apnea, thyroid problems, perimenopause and menopause, low testosterone, stress, pain, alcohol, caffeine timing, and medications can all get in the way. At Refresh Med Spa L.A. we look at the whole picture, including hormone balance, fatigue, and stress, because the right fix depends on the cause. If you snore loudly, wake gasping, or feel exhausted after a full night, please get evaluated for sleep apnea first.
Let’s talk about your sleep
Schedule a consultation and we’ll review your sleep, your history, and the options available to you, including where the science stands on newer approaches like DSIP.Request Appointment
Frequently Asked Questions About DSIP and Sleep
DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid neuropeptide first isolated in 1974. It was named for its association with delta, or slow-wave, sleep. Where it is made in the body and exactly how it works are still being studied.
Small clinical studies in people with chronic insomnia reported improved sleep efficiency, shorter time to fall asleep, and better daytime alertness. However, the studies were small and older, not every result was reproduced, and one double-blind trial found no change in how people rated their own sleep quality. Larger modern trials are needed.
No. DSIP, which the FDA calls emideltide, is not approved for any condition. In July 2026 an FDA advisory committee voted 6 to 7, with one abstention, not to recommend adding it to the compounding list. The vote is advisory and the FDA has not issued a final decision.
Melatonin is a hormone that signals sleep timing and has modest evidence for helping people fall asleep. DSIP is a neuropeptide thought to influence sleep regulation and stress signaling, and its mechanism is not established. They are different substances and are not interchangeable.
Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia. It is also important to rule out medical causes such as sleep apnea, thyroid problems, hormone changes, pain, stress, and medication effects. Talk with your physician before starting any new sleep aid.
References
- Kaeser HE. A clinical trial with DSIP. PMID 6391926. pubmed.ncbi.nlm.nih.gov/6391926
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Neuropsychobiology. 1987;27(2):120-129. PMID 3622582
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992;26(4):193-197. PMID 1299794
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006.
- U.S. FDA. Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (emideltide/DSIP). fda.gov
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. DSIP is not approved by the FDA for any condition. Individual results vary. Always consult your physician or other qualified health provider about a medical condition, and do not start, stop, or change any medication or supplement without medical guidance.